Sera Prognostics to Host Virtual R&D Day on January 31

Core Insights - Sera Prognostics Inc. is hosting a virtual R&D day on January 31, 2025, to present results from its pivotal PRIME study, focusing on improving maternal and neonatal health through innovative pregnancy biomarker information [1][2] Company Overview - Sera Prognostics is dedicated to enhancing the lives of women and babies by providing early pregnancy information aimed at improving health outcomes and reducing healthcare costs [4] - The company has a robust pipeline of diagnostic tests, including the PreTRM® Test, which predicts the risk of spontaneous preterm birth, allowing for proactive interventions [4][6] Study and Test Details - The PRIME study aims to assess the effectiveness of clinical interventions in improving neonatal outcomes related to preterm birth [2] - The PreTRM® Test is the only validated blood-based biomarker test that provides individualized risk predictions for spontaneous preterm birth in asymptomatic singleton pregnancies, enabling informed clinical decisions [6] Preterm Birth Context - Preterm birth, defined as any birth before 37 weeks' gestation, is a leading cause of illness and death in newborns, with significant long-term health implications and estimated annual healthcare costs of approximately $25 billion in the U.S. [5]